CONSUN PHARMAC.GR.HD -10 Market Cap ($1.35 Billion)
Market Cap & Net Worth: CONSUN PHARMAC.GR.HD -10 (C1P)
CONSUN PHARMAC.GR.HD -10 market cap. CONSUN PHARMAC.GR.HD -10 (F:C1P) has a market capitalization of $1.35 Billion (€1.15 Billion) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #7406 globally and #1040 in its home market, demonstrating a 0.60% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CONSUN PHARMAC.GR.HD -10's stock price €1.67 by its total outstanding shares 841408111 (841.41 Million). Also see cash efficiency ratio of CONSUN PHARMAC.GR.HD -10 for how efficiently the company converts equity into cash flow.
CONSUN PHARMAC.GR.HD -10 Market Cap History (2015–2026)
CONSUN PHARMAC.GR.HD -10 market cap history from 2015 to 2026. Data shows growth from $1.57 Million to $1.64 Billion (89.89% CAGR). Check CONSUN PHARMAC.GR.HD -10 share price for real-time trading data and today's change.
CONSUN PHARMAC.GR.HD -10 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CONSUN PHARMAC.GR.HD -10's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore C1P shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.47x
CONSUN PHARMAC.GR.HD -10's market cap is 0.47 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.50x
CONSUN PHARMAC.GR.HD -10's market cap is 1.50 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $35.61 Million | $2.04 Billion | $590.17 Million | 0.02x | 0.06x |
| 2022 | $62.17 Million | $2.34 Billion | $682.91 Million | 0.03x | 0.09x |
| 2023 | $201.66 Million | $2.59 Billion | $784.53 Million | 0.08x | 0.26x |
| 2024 | $1.01 Billion | $2.97 Billion | $910.46 Million | 0.34x | 1.11x |
| 2025 | $1.61 Billion | $3.42 Billion | $1.08 Billion | 0.47x | 1.50x |
Competitor Companies of C1P by Market Capitalization
Companies near CONSUN PHARMAC.GR.HD -10 in the global market cap rankings as of November 4, 2026. Also see how large is CONSUN PHARMAC.GR.HD -10's balance sheet for a full breakdown of the balance sheet.
Key companies related to CONSUN PHARMAC.GR.HD -10 by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $45.45 Billion USD ( CN¥310.59 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #516 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.55 |
| #591 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.45 Billion | CN¥48.69 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of CONSUN PHARMAC.GR.HD -10 (2015–2026)
Market capitalization of CONSUN PHARMAC.GR.HD -10 from 2015 to today. Between 2015 and today, CONSUN PHARMAC.GR.HD -10's market cap moved from $1.57 Million to $ 1.64 Billion, with a yearly change of 89.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.64 Billion | +1.83% |
| 2025 | €1.61 Billion | +59.22% |
| 2024 | €1.01 Billion | +402.44% |
| 2023 | €201.66 Million | +224.37% |
| 2022 | €62.17 Million | +74.59% |
| 2021 | €35.61 Million | +325.88% |
| 2020 | €8.36 Million | +6.25% |
| 2019 | €7.87 Million | +110.53% |
| 2018 | €3.74 Million | -26.92% |
| 2017 | €5.12 Million | +205.88% |
| 2016 | €1.67 Million | +6.25% |
| 2015 | €1.57 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of CONSUN PHARMAC.GR.HD -10 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.35 Billion USD |
| MoneyControl | $1.35 Billion USD |
| MarketWatch | $1.35 Billion USD |
| marketcap.company | $1.35 Billion USD |
| Reuters | $1.35 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CONSUN PHARMAC.GR.HD -10
Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney… Read more